K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine

Z. Gu, H. Salomon, J. M. Cherrington, A. S. Mulato, M. S. Chen, R. Yarchoan, A. Foli, K. M. Sogocio, M. A. Wainberg

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Cloned variants of human immunodeficiency virus type 1 that contain the K65R mutation in reverse transcriptase have previously been shown to display approximately 10- to 30-fold resistance against 2',3'-dideoxycytidine, 2',3'- dideoxyinosine, and 2',3'-dideoxy-3'-thiacytidine. On the basis of tissue culture studies with both primary T cells and established cell lines, we now report that the K65R mutation confers approximately 12- to 15-fold resistance to 9-(2-phosphonylmethoxyethyl)adenine (PMEA). Likewise, a chain termination system revealed that mutated recombinant K65R reverse transcriptase displays resistance to PMEA diphosphate, the active metabolite of PMEA, in cell-free enzyme assays. Parallel studies have shown that the M184V mutation in reverse transcriptase, associated with high-level resistance against the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine, does not confer resistance to PMEA in tissue culture. Viruses and enzymes that included both the K65R and M184V mutations were resistant to PMEA and PMEA diphosphate, respectively, but only to the extent conferred by the K65R mutation alone.

Original languageEnglish
Pages (from-to)1888-1891
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Volume39
Issue number8
Publication statusPublished - 1995

Fingerprint

HIV-1
Mutation
RNA-Directed DNA Polymerase
Lamivudine
Diphosphates
Zalcitabine
Didanosine
Enzyme Assays
Human immunodeficiency virus 1 reverse transcriptase
adefovir
Viruses
T-Lymphocytes
Cell Line
Enzymes

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Gu, Z., Salomon, H., Cherrington, J. M., Mulato, A. S., Chen, M. S., Yarchoan, R., ... Wainberg, M. A. (1995). K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine. Antimicrobial Agents and Chemotherapy, 39(8), 1888-1891.

K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine. / Gu, Z.; Salomon, H.; Cherrington, J. M.; Mulato, A. S.; Chen, M. S.; Yarchoan, R.; Foli, A.; Sogocio, K. M.; Wainberg, M. A.

In: Antimicrobial Agents and Chemotherapy, Vol. 39, No. 8, 1995, p. 1888-1891.

Research output: Contribution to journalArticle

Gu, Z, Salomon, H, Cherrington, JM, Mulato, AS, Chen, MS, Yarchoan, R, Foli, A, Sogocio, KM & Wainberg, MA 1995, 'K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine', Antimicrobial Agents and Chemotherapy, vol. 39, no. 8, pp. 1888-1891.
Gu, Z. ; Salomon, H. ; Cherrington, J. M. ; Mulato, A. S. ; Chen, M. S. ; Yarchoan, R. ; Foli, A. ; Sogocio, K. M. ; Wainberg, M. A. / K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine. In: Antimicrobial Agents and Chemotherapy. 1995 ; Vol. 39, No. 8. pp. 1888-1891.
@article{c4f7534bdfc74383b5e1351d1f1d2446,
title = "K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine",
abstract = "Cloned variants of human immunodeficiency virus type 1 that contain the K65R mutation in reverse transcriptase have previously been shown to display approximately 10- to 30-fold resistance against 2',3'-dideoxycytidine, 2',3'- dideoxyinosine, and 2',3'-dideoxy-3'-thiacytidine. On the basis of tissue culture studies with both primary T cells and established cell lines, we now report that the K65R mutation confers approximately 12- to 15-fold resistance to 9-(2-phosphonylmethoxyethyl)adenine (PMEA). Likewise, a chain termination system revealed that mutated recombinant K65R reverse transcriptase displays resistance to PMEA diphosphate, the active metabolite of PMEA, in cell-free enzyme assays. Parallel studies have shown that the M184V mutation in reverse transcriptase, associated with high-level resistance against the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine, does not confer resistance to PMEA in tissue culture. Viruses and enzymes that included both the K65R and M184V mutations were resistant to PMEA and PMEA diphosphate, respectively, but only to the extent conferred by the K65R mutation alone.",
author = "Z. Gu and H. Salomon and Cherrington, {J. M.} and Mulato, {A. S.} and Chen, {M. S.} and R. Yarchoan and A. Foli and Sogocio, {K. M.} and Wainberg, {M. A.}",
year = "1995",
language = "English",
volume = "39",
pages = "1888--1891",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "8",

}

TY - JOUR

T1 - K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine

AU - Gu, Z.

AU - Salomon, H.

AU - Cherrington, J. M.

AU - Mulato, A. S.

AU - Chen, M. S.

AU - Yarchoan, R.

AU - Foli, A.

AU - Sogocio, K. M.

AU - Wainberg, M. A.

PY - 1995

Y1 - 1995

N2 - Cloned variants of human immunodeficiency virus type 1 that contain the K65R mutation in reverse transcriptase have previously been shown to display approximately 10- to 30-fold resistance against 2',3'-dideoxycytidine, 2',3'- dideoxyinosine, and 2',3'-dideoxy-3'-thiacytidine. On the basis of tissue culture studies with both primary T cells and established cell lines, we now report that the K65R mutation confers approximately 12- to 15-fold resistance to 9-(2-phosphonylmethoxyethyl)adenine (PMEA). Likewise, a chain termination system revealed that mutated recombinant K65R reverse transcriptase displays resistance to PMEA diphosphate, the active metabolite of PMEA, in cell-free enzyme assays. Parallel studies have shown that the M184V mutation in reverse transcriptase, associated with high-level resistance against the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine, does not confer resistance to PMEA in tissue culture. Viruses and enzymes that included both the K65R and M184V mutations were resistant to PMEA and PMEA diphosphate, respectively, but only to the extent conferred by the K65R mutation alone.

AB - Cloned variants of human immunodeficiency virus type 1 that contain the K65R mutation in reverse transcriptase have previously been shown to display approximately 10- to 30-fold resistance against 2',3'-dideoxycytidine, 2',3'- dideoxyinosine, and 2',3'-dideoxy-3'-thiacytidine. On the basis of tissue culture studies with both primary T cells and established cell lines, we now report that the K65R mutation confers approximately 12- to 15-fold resistance to 9-(2-phosphonylmethoxyethyl)adenine (PMEA). Likewise, a chain termination system revealed that mutated recombinant K65R reverse transcriptase displays resistance to PMEA diphosphate, the active metabolite of PMEA, in cell-free enzyme assays. Parallel studies have shown that the M184V mutation in reverse transcriptase, associated with high-level resistance against the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine, does not confer resistance to PMEA in tissue culture. Viruses and enzymes that included both the K65R and M184V mutations were resistant to PMEA and PMEA diphosphate, respectively, but only to the extent conferred by the K65R mutation alone.

UR - http://www.scopus.com/inward/record.url?scp=0029154895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029154895&partnerID=8YFLogxK

M3 - Article

C2 - 7486942

AN - SCOPUS:0029154895

VL - 39

SP - 1888

EP - 1891

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 8

ER -